CClinicalTrials.gg
RecruitingNCT06573749Updated Apr 2, 2025

Effect of 12-week Milk Fat Globule Membrane Supplementation on the Human Muscle Function of Healthy, Recreationally Active Adults

An interventional study of Bioactive whey protein concentrate and Whey protein isolate supplement in Ageing Well and Neuromuscular Function, sponsored by Loughborough University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Loughborough University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main aim of this study is to understand if chronic supplementation (12 weeks) of a milk fat globule membrane containing supplement, called bioactive whey protein concentrate, improves human muscle function greater than a placebo supplement within a cohort of healthy, recreationally active adults. Furthermore, we aim to investigate whether any potential benefits of milk fat globule membrane are influenced by age through the assessment of 2 distinct age subgroups (young and older). We hypothesise that neuromuscular function (strength and power) will increase from pre to post within the group that consumes bioactive whey protein concentrate but not the placebo group, with a greater increase in the older group compared to the young group.

Read the detailed description

Nutritional strategies, including supplementation, are widely sought after to improve the function of the neuromuscular system (muscle strength and power). Milk fat globule membrane (MFGM, composed of the membrane that surrounds milk fat droplets) has begun to receive increasing attention as a potential supplement to improve muscle function and size due to a series of promising longitudinal studies (> 4 weeks of supplementation), however the overall findings are still conflicting which is likely due to methodological limitations of previous studies. Therefore, it is important to thoroughly investigate whether chronic supplementation of a MFGM-containing supplement is effective at improving the function and physiology of the neuromuscular system within healthy, recreationally active adults.

This study aims to compare the effects of chronic (12 weeks) bioactive whey protein concentrate (BWPC) supplementation versus an isocaloric, isonitrogenous whey protein isolate placebo on the physiology (contractile properties, coactivation, timing of action potentials), morphology (total/functional muscle cross-sectional area/volume), and function of the neuromuscular system of healthy, recreationally active adults.

Utilising a randomised, double-blind, parallel group study design, participants will be allocated to one of two groups: BWPC or placebo supplement group. Once consented, participants will complete screening questionnaires to confirm their eligibility. Altogether, participants will be required to attend 5 laboratory sessions (1 familiarisation \~ 1.5 hours, 4 main measurement sessions each \~ 2 hours) at the neuromuscular laboratories situated within the Matthew Arnold building at Loughborough University. The familiarisation and first two baseline measurement sessions will be done over a 2-week period, after which participants will be asked to consume a supplement daily for 12 weeks (84 daily doses) while they maintain their usual lifestyle (diet and exercise/physical activity). Then they will attend two further post measurement sessions, with the first being at exactly 12 weeks of supplementation (i.e. 84th day) and the second being 3-4 days later (i.e. 87th or 88th day). The supplementation protocol will involve participants mixing 1 scoop of supplement with water and consuming the resultant drink alongside their breakfast. Participants will be required to fill in a diet record form twice across the supplementation period (week 3 and 9), which involves weighing and recording what they eat/drink over 3 consecutive days. Physical activity at pre and post will be assessed through the International Physical Activity Questionnaire (IPAQ, short format).

During the familiarisation session participants will get to try all of the types of contractions (voluntary and involuntary) to be performed in the main measurement sessions, but without the recording of electromyography (EMG). The first measurement session at baseline/post will begin with countermovement jumps on a force plate. The remainder of the session will involve various isometric knee extension or flexion contractions within a custom-built isometric dynamometer. This will include maximal and explosive voluntary contractions to assess maximal strength of the knee extensors and flexors and rate of force development of the knee extensors, respectively. Supramaximal femoral nerve stimulation will be utilised to evoke twitch contractions of the knee extensors. Submaximal transcutaneous muscle stimulation will be performed to assess the force-frequency relationship (1 - 100 Hz) of the knee extensors. Finally, submaximal knee extension contractions (10 and 25% of maximal voluntary force) will be performed while a concentric needle electrode is inserted into the vastus lateralis to assess the stability of neuromuscular junction transmission. Throughout this measurement session, surface EMG signals will be collected by placing surface EMG electrodes on each of the 3 superficial quadriceps muscles (rectus femoris, vastus lateralis and medialis) and on the hamstrings (medial and lateral).

Within the second measurement session at pre/post, participant's will have an 3.0 T MRI scan of the lower limbs. The procedure will be clearly explained to the participant before they sign the MRI agreement form and fill in the MRI safety questionnaire.

For this study we want to assess whether any potential benefits of milk fat globule membrane are influenced by age. Therefore, we will be recruiting 2 subgroups (young 18 - 30 years old; older 60 - 75 years old). The power analysis was based on detecting a group by time interaction for isometric strength, with input parameters of: effect size = 0.15, alpha = 0.05, power = 0.8, correlation among repeated measures = 0.8. Altogether, 38 participants are needed as a minimum within each age group (19 per group). However, to account for a 25% drop-out rate, 48 participants will be recruited for each age group. The total number of participants recruited will be 96 (48 young, 48 older).

Statistical analysis will involve fitting linear mixed effect models to detect any main effects or interactions, with supplement group, time (pre vs post), and their interaction as fixed effects, and participant as a random intercept. Visual plots (histograms and quantile-quantile plots) will be used to verify the assumptions of normality, linearity, and homoscedasticity of residuals.

02

Conditions studied

  • Ageing Well
  • Neuromuscular Function

Keywords

  • Nutrition
  • Neuromuscular
  • Milk fat globule membrane
03

In context

Lead sponsor

Loughborough University is the lead sponsor of 71 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18-30 or 60-75 years old
  • Male or female
  • Healthy with no contraindications to exercise
  • Classified as recreationally active (meet the government's guidelines for weekly physical activity - 150 minutes of moderate physical activity or 75 minutes of vigorous physical activity)

Exclusion criteria

Exclusion Criteria:

  • Any injury, medical condition or symptom precluding the ability to complete strenuous exercise as identified by the health screen questionnaire and physical activity readiness questionnaire
  • Uncontrolled hypertension (blood pressure of 140/90 mmHg or higher) as identified by recording resting blood pressure
  • Neuromuscular or musculoskeletal disease
  • Occurrence of a severe injury to the lower limbs or back within the previous 6 months (time loss of > 21 days of normal activity)
  • Occurrence of a minor injury to the lower limbs or back within the previous month (time loss of >1 day of normal activity)
  • Do not meet the government guidelines of minimum weekly physical activity as revealed by the IPAQ-SF
  • Allergic to dairy or pea, or lactose intolerant
  • Complete greater than 6 hours structured exercise per week as revealed by the exercise and physical activity form
  • Consumption of supplements that may confound the results of the present study within the previous 3 months (includes any form of protein supplement, creatine, pre-workout supplements, any form of testosterone supplement, amino acids, beta-alanine, beta- hydroxy-beta-methylbutyrate (HMB), fish or krill oil, collagen supplements, any choline- containing supplement, or any phospholipid-containing supplement) as highlighted by the health screen questionnaire
  • Taking anticoagulants or antiplatelet drugs
  • Use of antidepressant/anti-anxiety medication
  • Having a blood borne virus, or a partner who has a blood-borne virus
  • Extreme diet classified as identified by the food-frequency questionnaire
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Bioactive whey protein concentrate supplement group

    This group will consume a supplement called bioactive whey protein concentrate, a whey protein concentrate that contains milk fat globule membrane.

    Dietary Supplement: Bioactive whey protein concentrate

  • Placebo comparator
    Placebo group

    This group will consume an isocaloric, isonitrogenous whey protein isolate supplement that does not contain phospholipids or sphingomyelin. Dextrose has been added to the whey protein isolate to ensure the 2 supplements are isocaloric.

    Dietary Supplement: Whey protein isolate supplement

Interventions

  • Dietary supplementBioactive whey protein concentrate

    Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.

  • Dietary supplementWhey protein isolate supplement

    Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.

06

What researchers measure

Primary outcomes

  1. Maximal voluntary isometric torque of the knee extensors

    Assessed during maximal voluntary contractions (Nm)

    Time frame: 12 weeks

Secondary outcomes

  1. Rate of torque development of the knee extensors

    Assessed during explosive isometric contractions (Nm/s)

    Time frame: 12 weeks

  2. Peak twitch torque (knee extensors)

    (Nm)

    Time frame: 12 weeks

  3. Time to peak twitch torque (knee extensors)

    (ms)

    Time frame: 12 weeks

  4. Half-relaxation time during twitch contractions (knee extensors)

    (ms)

    Time frame: 12 weeks

  5. Neural activation of the agonist (quadriceps) and antagonist (hamstrings)

    Surface electromyography (root mean square amplitude)

    Time frame: 12 weeks

  6. Force-frequency relationship of the knee extensors

    Peak torque across the various stimulation frequencies (1 - 100 Hz, Nm)

    Time frame: 12 weeks

  7. Neuromuscular junction transmission stability

    Extraction of variables (e.g. jitter and jiggle) from the decomposition of intramuscular electromyography signals recorded during submaximal (10 and 25% of maximal voluntary force) isometric knee extension contractions held for 20 seconds

    Time frame: 12 weeks

  8. Cross-sectional area of upper leg muscles

    Measured by MRI (cm\^2)

    Time frame: 12 weeks

  9. Volume of upper leg muscles

    Measured by MRI (cm\^3)

    Time frame: 12 weeks

  10. Functional cross-sectional area of upper leg muscles

    Measured by MRI (cm\^2)

    Time frame: 12 weeks

  11. Functional volume of upper leg muscles

    Measured by MRI (cm\^3)

    Time frame: 12 weeks

  12. Intramuscular fat infiltration of upper leg muscles

    Measured by MRI (% of intramuscular fat)

    Time frame: 12 weeks

  13. Neuromuscular power

    Measured during countermovement jumps on a force plate (W)

    Time frame: 12 weeks

  14. Level of physical activity

    International Physical Activity Questionnaire (IPAQ)

    Time frame: 12 weeks

  15. Habitual energy intake

    Measured by food diary (kcal.day-1)

    Time frame: 12 weeks

  16. Habitual protein intake

    Measured by food diary (g.day-1)

    Time frame: 12 weeks

  17. Habitual carbohydrate intake

    Measured by food diary (g.day-1)

    Time frame: 12 weeks

  18. Habitual fibre intake

    Measured by food diary (g.day-1)

    Time frame: 12 weeks

  19. Habitual fat intake

    Measured by food diary (g.day-1)

    Time frame: 12 weeks

  20. Habitual choline intake

    Measured by food diary (mg.day-1)

    Time frame: 12 weeks

  21. Maximum voluntary isometric torque of the knee flexors

    Assessed during maximal voluntary contractions (Nm)

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Loughborough University
    Loughborough, Leicestershire LE11 3TU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573749
Lead sponsor
Loughborough University
Collaborators
Volac International Limited
Responsible party
Edward Sadula (Doctoral Researcher, Loughborough University) — Principal investigator
First posted
Aug 27, 2024
Start date
Mar 28, 2025
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Apr 2, 2025

Study contacts

Edward Sadula, BSc, MSc
Contact
e.sadula2@lboro.ac.uk
07477 866809
Jonathan Folland, BSc, PhD
Contact
J.P.Folland@lboro.ac.uk
01509 226334
Edward Sadula, BSc, MSc
principal investigator · Loughborough University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion